Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

16.75 -0.01 (-0.03%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

October 02, 2026

From Summit Therapeutics

Via Business Wire

These stocks that are showing activity before the opening bell on Tuesday. ↗

September 29, 2026

Via Chartmill

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics

September 28, 2026

From Summit Therapeutics

Via Business Wire

HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026

September 22, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics (SMMT) Reports In-Line Q2 Loss; Stock Eases Amid Pivotal PDUFA Catalyst ↗

July 23, 2026

Via Chartmill

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

September 15, 2026

From Summit Therapeutics

Via Business Wire

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China

September 13, 2026

From Summit Therapeutics

Via Business Wire

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

September 02, 2026

From Summit Therapeutics

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 26, 2026

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.0 million. Summit Therapeutics...

Via Benzinga

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

August 25, 2026

From Summit Therapeutics

Via Business Wire

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

August 25, 2026

From Summit Therapeutics

Via Business Wire

GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity ↗

August 24, 2026

Could these 2 stocks outperform most GLP-1-focused companies over the medium term?

Via The Motley Fool

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

August 12, 2026

From Summit Therapeutics

Via Business Wire

Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty

August 06, 2026

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

August 05, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Q2 Earnings Call Highlights ↗

July 23, 2026

Summit Therapeutics (NASDAQ:SMMT) executives used the company’s latest earnings call to emphasize updated survival data for ivonescimab, outline the timing of key late-stage trial readouts and detail...

Via MarketBeat

Topics Earnings

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

July 23, 2026

From Summit Therapeutics

Via Business Wire

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

July 22, 2026

From Summit Therapeutics

Via Business Wire

Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study

July 22, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

July 16, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.

July 14, 2026

From Summit Therapeutics

Via Business Wire

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 30, 2026

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

Via The Motley Fool

Topics Artificial Intelligence

Summit Therapeutics Announces Proposed Public Offering of Common Stock

June 09, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference

June 04, 2026

From Summit Therapeutics

Via Business Wire

This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced ↗

May 31, 2026

Biotech companies have always licensed programs, but never so many from one region in particular.

Via The Motley Fool

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

May 31, 2026

From Summit Therapeutics

Via Business Wire

Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

May 30, 2026

From Summit Therapeutics

Via Business Wire

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗

May 23, 2026

This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗

May 23, 2026

Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.

Via The Motley Fool

A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology

May 14, 2026

From USA News Group

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.